article thumbnail

There’s An Easier Way to Take Insulin, But It Hasn’t Been Tested on People Yet

AuroBlog - Aurous Healthcare Clinical Trials blog

The most effective way for people with diabetes to deliver insulin is also incredibly intrusive. Millions around the world must inject the crucial hormone underneath their skin several times a day to keep their glucose levels in balance.

Insulin 194
article thumbnail

Velocity Investigators Active at the American Diabetes Association (ADA) 83rd Scientific Sessions

Velocity Clinical Research

Rosenstock is the lead investigator for Novo Nordisk’s ONWARDS 1 program exploring the first investigational once-weekly insulin. “In In ONWARDS 1, insulin icodec allowed people to spend significantly more Time in Range, with comparable Time below Range vs. once-daily basal insulin glargine U100,” said Dr. Rosenstock. “A

Insulin 52
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Lilly collaborates internationally with leading diabetes technology companies to integrate connected insulin pen solutions for people with diabetes | Eli Lilly and Company

The Pharma Data

The Tempo Pen is a modified version of Lilly ‘s existing prefilled, disposable insulin pen to which the Tempo Smart Button – pending CE (Conformité Européenne or European Conformity) marking – attaches. Diabetes is a chronic disease that occurs when the body does not properly produce or use the hormone insulin.

Insulin 52
article thumbnail

Diamyd Medical and Critical Path Institute announce data sharing collaboration to develop advanced drug development tools in type 1 diabetes

The Pharma Data

The Phase III trial evaluated the use of the diabetes vaccine Diamyd ® , an antigen-specific immunotherapy based on the auto-antigen GAD (glutamic acid decarboxylase), to induce immunological tolerance and stop the autoimmune destruction of insulin producing cells. People with type 1 diabetes cannot produce insulin.

article thumbnail

Surrogate Endpoints: How to Choose the Best One for Your Rare Disease Trial

XTalks

While clinical researchers occasionally need to identify and validate a new surrogate endpoint for a given trial, choosing endpoints that have been previously used as the basis of NDAs and BLAs can clear the path to eventual approval. The tumor secretes adrenocorticotropic hormone (ACTH), which stimulates cortisol production.

Trials 98
article thumbnail

Let's Quit Sugar With Audiobook – Let's Quit Sugar

The Pharma Data

Following this program will help you lose weight fast, prevent yo-yoing, stabilize hormonal balance, and get back on track to leading a healthy life – all while never being hungry or having to go to the gym! Effects of glucose-to-fructose ratios in solutions on subjective satiety, food intake, and satiety hormones in young men.

Insulin 52
article thumbnail

FDA Approves Merck’s KEYTRUDA® (pembrolizumab) in Combination With Padcev® (enfortumab vedotin-ejfv) for First-Line Treatment of Certain Patients With Locally Advanced or Metastatic Urothelial Cancer

The Pharma Data

Merck has the industry’s largest immuno-oncology clinical research program. The KEYTRUDA clinical program seeks to understand the role of KEYTRUDA across cancers and the factors that may predict a patient’s likelihood of benefitting from treatment with KEYTRUDA, including exploring several different biomarkers.